Synonym
Esmolol Hydrochloride; Esmolol HCl; Brevibloc; Esmolol (hydrochloride); ASL-8052; Asl 8052; ASL 8052;
IUPAC/Chemical Name
methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate; hydrochloride
InChi Key
GEKNCWBANDDJJL-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H25NO4.ClH/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3;/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3;1H
SMILES Code
CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O.Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Esmolol hydrochloride is a beta adrenergic receptor blocker.
In vitro activity:
The results indicated that esmolol reversibly inhibited I(Na) in a concentration-dependent manner, with an IC50 of 74.2 +/- 0.60 micromol l(-1) with a Hill coefficient of 1.02 +/- 0.04. This inhibition was voltage- and frequency-dependent.
Reference: Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):697-702. https://pubmed.ncbi.nlm.nih.gov/17235414/
In vivo activity:
Brain histology showed a significant reduction in cortical neuronal degeneration/necrosis in the esmolol group compared to the control one (mean score 0.3 vs. 1.3, p = 0.03, Fig. 3A), while only a trend was present in the hippocampal region (mean score 1 vs. 2, p = 0.11, Fig. 3B). A marked reduction of microglial activation in the hippocampus was also observed after treatment with esmolol compared to control (mean % 6 vs. 2, p < 0.001, Fig. 3C). Significantly lower circulating levels of NSE were measured in esmolol animals compared to controls at 96 h after resuscitation (median 2.2 vs. 21, p < 0.0001, Fig. 4A).
Reference: Sci Rep. 2021; 11: 10635. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138021/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMSO |
63.7 |
191.87 |
|
| DMF |
25.0 |
75.34 |
|
| Ethanol |
45.5 |
137.11 |
|
| PBS (pH 7.2) |
10.0 |
30.14 |
|
| Water |
58.0 |
174.78 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
331.84
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Deng CY, Lin SG, Zhang WC, Kuang SJ, Qian WM, Wu SL, Shan ZX, Yang M, Yu XY. Esmolol inhibits Na+ current in rat ventricular myocytes. Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):697-702. doi: 10.1358/mf.2006.28.10.1037498. PMID: 17235414.
2. Gorelik J, Vodyanoy I, Shevchuk AI, Diakonov IA, Lab MJ, Korchev YE. Esmolol is antiarrhythmic in doxorubicin-induced arrhythmia in cultured cardiomyocytes - determination by novel rapid cardiomyocyte assay. FEBS Lett. 2003 Jul 31;548(1-3):74-8. doi: 10.1016/s0014-5793(03)00743-9. PMID: 12885410.
3. Ruggeri L, Nespoli F, Ristagno G, Fumagalli F, Boccardo A, Olivari D, Affatato R, Novelli D, De Giorgio D, Romanelli P, Minoli L, Cucino A, Babini G, Staszewsky L, Zani D, Pravettoni D, Belloli A, Scanziani E, Latini R, Magliocca A. Esmolol during cardiopulmonary resuscitation reduces neurological injury in a porcine model of cardiac arrest. Sci Rep. 2021 May 20;11(1):10635. doi: 10.1038/s41598-021-90202-w. PMID: 34017043; PMCID: PMC8138021.
4. Hoareau GL, Beyer CA, Caples CM, Spruce MW, Gilbert Z, Grayson JK, Neff LP, Williams TK, Johnson MA. Esmolol reduces myocardial injury induced by resuscitative endovascular balloon occlusion of the aorta (REBOA) in a porcine model of hemorrhagic shock. Injury. 2020 Oct;51(10):2165-2171. doi: 10.1016/j.injury.2020.07.005. Epub 2020 Jul 3. PMID: 32669205.
In vitro protocol:
1. Deng CY, Lin SG, Zhang WC, Kuang SJ, Qian WM, Wu SL, Shan ZX, Yang M, Yu XY. Esmolol inhibits Na+ current in rat ventricular myocytes. Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):697-702. doi: 10.1358/mf.2006.28.10.1037498. PMID: 17235414.
2. Gorelik J, Vodyanoy I, Shevchuk AI, Diakonov IA, Lab MJ, Korchev YE. Esmolol is antiarrhythmic in doxorubicin-induced arrhythmia in cultured cardiomyocytes - determination by novel rapid cardiomyocyte assay. FEBS Lett. 2003 Jul 31;548(1-3):74-8. doi: 10.1016/s0014-5793(03)00743-9. PMID: 12885410.
In vivo protocol:
1. Ruggeri L, Nespoli F, Ristagno G, Fumagalli F, Boccardo A, Olivari D, Affatato R, Novelli D, De Giorgio D, Romanelli P, Minoli L, Cucino A, Babini G, Staszewsky L, Zani D, Pravettoni D, Belloli A, Scanziani E, Latini R, Magliocca A. Esmolol during cardiopulmonary resuscitation reduces neurological injury in a porcine model of cardiac arrest. Sci Rep. 2021 May 20;11(1):10635. doi: 10.1038/s41598-021-90202-w. PMID: 34017043; PMCID: PMC8138021.
2. Hoareau GL, Beyer CA, Caples CM, Spruce MW, Gilbert Z, Grayson JK, Neff LP, Williams TK, Johnson MA. Esmolol reduces myocardial injury induced by resuscitative endovascular balloon occlusion of the aorta (REBOA) in a porcine model of hemorrhagic shock. Injury. 2020 Oct;51(10):2165-2171. doi: 10.1016/j.injury.2020.07.005. Epub 2020 Jul 3. PMID: 32669205.
1: Zhao B, Sun W. Incompatibility of esmolol hydrochloride and furosemide in a
central venous access port. Am J Health Syst Pharm. 2014 Jun 1;71(11):901-2. doi:
10.2146/ajhp130526. PubMed PMID: 24830993.
2: Baaske DM, Dykstra SD, Wagenknecht DM, Karnatz NN. Stability of esmolol
hydrochloride in intravenous solutions. Am J Hosp Pharm. 1994 Nov
1;51(21):2693-6. PubMed PMID: 7856582.
3: Vucevic M, Purdy GM, Ellis FR. Esmolol hydrochloride for management of the
cardiovascular stress responses to laryngoscopy and tracheal intubation. Br J
Anaesth. 1992 May;68(5):529-30. PubMed PMID: 1642945.
4: Karnatz NN, Wong J, Baaske DM, Johnson JH, Speicher ER, Herbranson DE.
Stability of esmolol hydrochloride and sodium nitroprusside in intravenous
admixtures. Am J Hosp Pharm. 1989 Jan;46(1):101-4. PubMed PMID: 2565685.
5: Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol
hydrochloride and various injectable drugs during simulated Y-site injection. Am
J Hosp Pharm. 1988 Mar;45(3):630-2. Erratum in: Am J Hosp Pharm 1988
Jun;45(6):1281. PubMed PMID: 2897164.
6: Wiest DB, Garner SS, Childress LM. Stability of esmolol hydrochloride in 5%
dextrose injection. Am J Health Syst Pharm. 1995 Apr 1;52(7):716-8. PubMed PMID:
7627740.
7: Jordan D, Shulman SM, Miller ED Jr. Esmolol hydrochloride, sodium
nitroprusside, and isoflurane differ in their ability to alter peripheral
sympathetic responses. Anesth Analg. 1993 Aug;77(2):281-90. PubMed PMID: 8102224.
8: Schaaf LJ, Robinson DH, Vogel GJ, Wulf BG, Drda KD, Moses JO. Stability of
esmolol hydrochloride in the presence of aminophylline, bretylium tosylate,
heparin sodium, and procainamide hydrochloride. Am J Hosp Pharm. 1990
Jul;47(7):1567-71. PubMed PMID: 2368749.
9: Karnatz NN, Wong J, Kesler H, Baaske DM, Speicher ER. Compatibility of esmolol
hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site
administration. Am J Hosp Pharm. 1988 Feb;45(2):368-71. PubMed PMID: 2896460.
10: Thompson DF, Thompson GD. Visual compatibility of esmolol hydrochloride and
furosemide in 5% dextrose or 0.9% sodium chloride injections. Am J Hosp Pharm.
1987 Dec;44(12):2740. PubMed PMID: 3434585.
11: Angaran DM, Schultz NJ, Tschida VH. Esmolol hydrochloride: an
ultrashort-acting, beta-adrenergic blocking agent. Clin Pharm. 1986
Apr;5(4):288-303. Review. PubMed PMID: 2871961.
12: Karnatz NN, Baaske DM, Herbranson DE, Eliason MS. High-performance liquid
chromatographic method for the determination of esmolol hydrochloride in
solutions and parenteral formulations. J Chromatogr. 1985 Aug 23;330(2):420-4.
PubMed PMID: 4066833.
13: Lee YC, Baaske DM, Alam AS. High-performance liquid chromatographic method
for the determination of esmolol hydrochloride. J Pharm Sci. 1984
Nov;73(11):1660-1. PubMed PMID: 6520778.
